Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

Investing.com -- FibroGen Inc (NASDAQ: FGEN) stock jumped 9.9% following positive feedback from the U.S. Food and Drug Administration supporting the advancement of roxadustat for treating anemia in ...

FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic ...

Total knee arthroplasty is a commonly performed procedure with postoperative complications including blood loss, pain, and ...

The post mortem reports of three lion cubs who died in Gujarat’s Amreli district recently have cited anemia and pneumonia as the causes, a senior forest department official said on Friday. Two of the ...

HDFN is a common cause of fetal anemia in infants, and it can lead to serious complications if not treated early.

Local blood drives are popping up this summer, traditionally a time when blood donations are at the lowest levels, and ...

Technological advances and new tools may offer the best chance to help underdeveloped blood deserts in the short term.

Download Free Sample of This Strategic Report with Industry Analysis @ The Saudi Arabia Blood Banking Market holds significant importance within the healthcare landscape of the country. Blood banking ...

The artificial blood cells market is an emerging and transformative segment in the biomedical industry, aimed at addressing the limitations of traditional blood transfusion methods.

A research team has successfully tested a blood substitute in animals, and human trials may not be far off. The powdered ...

The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl ...